BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28407529)

  • 1. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
    Adam R; Yi B; Innominato PF; Barroso E; Laurent C; Giuliante F; Capussotti L; Lapointe R; Regimbeau JM; Lopez-Ben S; Isoniemi H; Hubert C; Lin JK; Gruenberger T; Elias D; Skipenko OG; Guglielmi A;
    Eur J Cancer; 2017 Jun; 78():7-15. PubMed ID: 28407529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens.
    Truant S; Séquier C; Leteurtre E; Boleslawski E; Elamrani M; Huet G; Duhamel A; Hebbar M; Pruvot FR
    HPB (Oxford); 2015 Feb; 17(2):176-84. PubMed ID: 25041611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis.
    Sugiyama M; Uehara H; Shin Y; Shiokawa K; Fujimoto Y; Mano Y; Komoda M; Nakashima Y; Sugimachi K; Yamamoto M; Morita M; Toh Y
    Surg Today; 2022 Apr; 52(4):633-642. PubMed ID: 34762175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases.
    Conrad C; Vauthey JN; Masayuki O; Sheth RA; Yamashita S; Passot G; Bailey CE; Zorzi D; Kopetz S; Aloia TA; You YN
    Ann Surg Oncol; 2017 Dec; 24(13):3857-3864. PubMed ID: 28929463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver resection and ablation for metastatic melanoma: A single center experience.
    Doussot A; Nardin C; Takaki H; Litchman TD; D'Angelica MI; Jarnagin WR; Postow MA; Erinjeri JP; Kingham TP
    J Surg Oncol; 2015 Jun; 111(8):962-8. PubMed ID: 26073980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer.
    Bartolini I; Ringressi MN; Melli F; Risaliti M; Brugia M; Mini E; Batignani G; Bechi P; Boni L; Taddei A
    Gastroenterol Res Pract; 2018; 2018():5353727. PubMed ID: 30116264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection.
    Torén W; Sasor A; Ansari D; Andersson R
    Anticancer Res; 2024 Jun; 44(6):2597-2604. PubMed ID: 38821620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Resection for Synchronous Colorectal Liver Metastasis: the New Standard of Care?
    Abelson JS; Michelassi F; Sun T; Mao J; Milsom J; Samstein B; Sedrakyan A; Yeo HL
    J Gastrointest Surg; 2017 Jun; 21(6):975-982. PubMed ID: 28411351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
    Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
    Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
    Rivera F; Karthaus M; Hecht JR; Sevilla I; Forget F; Fasola G; Canon JL; Guan X; Demonty G; Schwartzberg LS
    Int J Colorectal Dis; 2017 Aug; 32(8):1179-1190. PubMed ID: 28424871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
    Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
    J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    Modest DP; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Scheithauer W; Moehler M; Westphalen CB; Holch JW; von Einem JC; Held S; Heinemann V;
    Eur J Cancer; 2017 Oct; 84():262-269. PubMed ID: 28843184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial.
    Rouanet P; Rullier E; Lelong B; Maingon P; Tuech JJ; Pezet D; Castan F; Nougaret S;
    Dis Colon Rectum; 2017 Jul; 60(7):653-663. PubMed ID: 28594714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.
    Groot Koerkamp B; Sadot E; Kemeny NE; Gönen M; Leal JN; Allen PJ; Cercek A; DeMatteo RP; Kingham TP; Jarnagin WR; D'Angelica MI
    J Clin Oncol; 2017 Jun; 35(17):1938-1944. PubMed ID: 28426374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
    Renfro LA; Goldberg RM; Grothey A; Sobrero A; Adams R; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Hoff PM; Kabbinavar FF; Falcone A; Tebbutt NC; Punt CJA; Hecht JR; Souglakos J; Bokemeyer C; Van Cutsem E; Saltz L; de Gramont A; Sargent DJ;
    J Clin Oncol; 2017 Jun; 35(17):1929-1937. PubMed ID: 28414610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Lévi F; Karaboué A; Saffroy R; Desterke C; Boige V; Smith D; Hebbar M; Innominato P; Taieb J; Carvalho C; Guimbaud R; Focan C; Bouchahda M; Adam R; Ducreux M; Milano G; Lemoine A
    Br J Cancer; 2017 Sep; 117(7):965-973. PubMed ID: 28817838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
    Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
    Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.